8.14 USD
↘ 0.23 (2.75%)AT CLOSE (11:59 AM EDT)
ImmunityBio, Inc. Common Stock
IBRXNASDAQ • USD
8.10
↘ 0.04 (0.55%)
POST MARKET (AS OF 07:58 PM EDT)
Post Market
AS OF 07:58 PM EDT
8.10
↘ 0.04 (0.55%)
Market: CLOSED
IBRX is currently priced at $8.15. The stock presents a mixed profile: our models indicate a Buy for technical indicators, while underlying fundamentals flash a Sell. Notable factors include a concerning Altman Z-Score in the distress zone, exceptional Return on Equity (94.8%), a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation-wise, the stock is priced at a premium — multiples like P/E and EV/EBITDA sit above sector averages.
Technical & fundamental data as of Sep 15, 2026.
Open?$8.32
High?$8.34
Low?$7.85
Prev. Close?$8.37
Volume?8.9M
Avg. Volume?8.3M
VWAP?$8.04
Rel. Volume?1.08x
Bid / Ask
Bid?$6.95 × 100
Ask?$9.20 × 100
Spread?$2.25
Midpoint?$8.08
Valuation & Ratios
Market Cap?8.9B
Shares Out?1.1B
Float?395.0M
Float %?37.3%
P/E Ratio?N/A
P/B Ratio?-8.48
EPS?-$0.94
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Themes
Employees
691
Market Cap
8.9B
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2021-03-10
Address
3530 JOHN HOPKINS COURT
SAN DIEGO, CA 92121
Phone: (844) 696-5235
SAN DIEGO, CA 92121
Phone: (844) 696-5235
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+2/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?23
Z-Score?0
Momentum?87
Short Sent.?30
Piotroski F-Score?3/9Weak
Altman Z-Score?-7.41Distress
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?31.81%Squeeze Risk
Short Interest?125.6M
Days to Cover?14.8
Free Float395.0M
Avg Daily Volume8.5M
Settlement Date2026-08-31
Financial Health
Current Ratio?5.72Strong
Quick Ratio?5.70Strong
Cash Ratio?0.99Adequate
Debt/Equity?-0.40Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?-8.48CHEAP▾
S&P97
P/S?53.51HIGH▾
Peers100
S&P3
P/FCF?N/A▾
EV/EBITDA?-39.2CHEAP▾
S&P97
EV/Sales?55.55HIGH▾
Peers100
S&P3
Returns & Efficiency
ROE?94.8%STRONG▾
Peers50
S&P97
ROA?-157.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-288074000
Enterprise Value?$9.2B
Fundamentals ratios updated end of day